Khiron Life Sciences Corp. announced that the Company has closed the previously announced MOU with Dayacann. As the dominant medical cannabis company in Latin America, this agreement expands on Khiron's multi jurisdiction cultivation strategy, securing access to cannabis cultivation for the Company's use in Chile, participation in clinical trials, and access to commercialize products to meet the needs of a market of 1.8 Million patients across the country. As previously announced on September 27, 2018, by entering into an MOU with Dayacann, Khiron identified its intent to operate in the Chilean market with all applicable regulatory approvals and cultivation capacity, to participate in clinical trials and to develop and distribute medical cannabis products in Chile. The Company has now completed an agreement with Dayacann to deliver on this strategy, encompassing clinical trials, cultivation and the commercialization of Khiron products to serve the Chilean market, all under an initial 2-year agreement, which gives the Company access to a cultivation capacity that can meet the needs of more than 45.000 patients annually. This agreement is subject to TSX approval.